

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHIA TAI ENTERPRISES INTERNATIONAL LIMITED**

**正大企業國際有限公司**

*(Incorporated in Bermuda with members' limited liability)*

(Stock Code: 3839)

### **RE-DESIGNATION OF DIRECTOR, CHANGE OF DIRECTOR, CHIEF EXECUTIVE OFFICER AND COMPOSITION OF BOARD COMMITTEE**

The board of directors (the “Board”) of Chia Tai Enterprises International Limited (the “Company”, together with its subsidiaries, the “Group”) announces the following changes with effect from 24 February 2026:

- (1) Mr. Soopakij Chearavanont (“Mr. Chearavanont”), the Chairman of the Company, has been re-designated from a non-executive director of the Company to an executive director of the Company as he will take on an executive role in the Group;
- (2) Mr. Thanakorn Seriburi (“Mr. Seriburi”) resigned as an executive director and Chief Executive Officer (Industrial Division) of the Company as he would like to devote more time to his other personal commitments. Consequently, Mr. Seriburi ceased to be a member of the remuneration committee of the Board (the “Remuneration Committee”);
- (3) Ms. Kobboon Srichai (“Ms. Srichai”) has been appointed as a non-executive director of the Company;
- (4) Mr. Chawalit Na Muangtoun (“Mr. Na Muangtoun”), currently an executive director of the Company, has been appointed as the Chief Executive Officer of the Company and a member of the Remuneration Committee; and
- (5) Mr. Thirayut Phityaisarakul (“Mr. Phityaisarakul”) ceased to be the Chief Executive Officer (Biochemical Division) of the Company following the appointment of Mr. Na Muangtoun, while he remains as an executive director of the Company.

Each of Mr. Seriburi and Mr. Phityaisarakul has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company.

The biography details of Mr. Chearavanont, Ms. Srichai and Mr. Na Muangtoun are as follows:

Mr. Soopakij Chearavanont, aged 61, has been the Chairman of the Company since September 2014. He was a non-executive director of the Company from September 2014 to February 2026 and re-designated as an executive director of the Company with effect from 24 February 2026. He was

chairman of the nomination committee of the Company from September 2014 to February 2024. He is a director of several subsidiaries of the Company. Mr. Chearavanont has extensive multinational investment and management experience in various industries. He is the chairman of Charoen Pokphand Group Company Limited and holds directorships in the following listed companies: a director and the chairman of CP ALL Public Company Limited and Charoen Pokphand Foods Public Company Limited (companies listed on the Stock Exchange of Thailand); a non-executive director of Ping An Insurance (Group) Company of China, Ltd. (a company listed on the Main Board of The Stock Exchange of Hong Kong Limited and the Shanghai Stock Exchange); and a non-executive director of Honma Golf Limited (a company listed on the Main Board of The Stock Exchange of Hong Kong Limited). He was previously a director of True Corporation Public Company Limited (a company listed on the Stock Exchange of Thailand). Mr. Chearavanont obtained a Bachelor of Science degree from the College of Business and Public Administration of New York University, USA. Mr. Chearavanont is a cousin of Mr. Nopadol Chiaravanont.

There is no service contract entered into between the Company and Mr. Chearavanont in relation to his re-designation as an executive director of the Company. Mr. Chearavanont has not been appointed for a specific term but shall be subject to retirement by rotation and re-election at annual general meetings in accordance with the bye-laws of the Company (“Bye-Laws”). Mr. Chearavanont will not receive remuneration in his position as Chairman and an executive director of the Company.

Ms. Kobboon Srichai, aged 59, joined Charoen Pokphand Foods Public Company Limited (“CPF”) (a company listed on the Stock Exchange of Thailand), a substantial shareholder of the Company, in 1995 and is currently the Company Secretary and Head of Corporate Affairs and Investor Relations of CPF. Ms. Srichai is also a director of several subsidiaries of CPF. Ms. Srichai is currently an Independent Director, a member of the Audit Committee, Chair of the Risk Committee and a member of the Governance and Sustainability Committee of Siam Wellness Group Public Company Limited (a company listed on the Stock Exchange of Thailand). Ms. Srichai obtained a Bachelor of Law from Thammasat University, Thailand and a Master of Business Administration from Azusa Pacific University, USA. Ms. Srichai currently serves as a member of the Subcommittee on Consideration of Regulations on Issuance and Offering of Equity Instruments, Governance of Securities Issuing Companies and Securities Acquisition for Business Takeovers of The Securities and Exchange Commission, Thailand.

Ms. Srichai has been appointed as a non-executive director of the Company pursuant to a letter of appointment but there is no service contract entered into between the Company and Ms. Srichai. Ms. Srichai has not been appointed for a specific term but shall be subject to retirement by rotation and re-election at annual general meetings in accordance with the Bye-Laws. Under the letter of appointment, Ms. Srichai will not receive any remuneration as a non-executive director of the Company. In accordance with the Bye-Laws, Ms. Srichai will hold office until the next annual general meeting of the Company and will be eligible for re-election.

Ms. Srichai has obtained the legal advice pursuant to Rule 3.09D of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and has confirmed that she understood her obligations as a director of the Company.

Mr. Chawalit Na Muangtoun, aged 59, has been an executive director of the Company and a member of the Corporate Governance Committee since February 2019. Mr. Na Muangtoun has been appointed as the Chief Executive Officer of the Company and a member of the Remuneration Committee with effect from 24 February 2026. He is currently a senior executive of the Group primarily responsible for the management of the Group’s biochemical business in China. Mr. Na Muangtoun also holds directorships in several companies within the Group. Mr. Na Muangtoun has been working for the Group since 1992. Mr. Na Muangtoun received a Bachelor degree in Accounting from Payap University in Thailand in 1989.

There is no service contract entered into between the Company and Mr. Na Muangtoun in relation to his appointment as an executive director and the Chief Executive Officer of the Company. Mr. Na Muangtoun has not been appointed as an executive director and the Chief Executive Officer of the Company for a specific term but his appointment as an executive director of the Company shall be subject to retirement by rotation and re-election at annual general meetings in accordance with the Bye-Laws. Mr. Na Muangtoun will not receive remuneration in his position as the Chief Executive Officer of the Company, and will receive remuneration which was determined by the Company with reference to his duties and responsibilities within the Group.

As at the date of this announcement, save as disclosed above, each of Mr. Chearavanont, Ms. Srichai and Mr. Na Muangtoun does not (1) hold any other positions with the Company or other members of the Group, (2) have any other major appointments and professional qualifications, (3) hold any directorships in any public companies whose securities are listed on any securities market in Hong Kong or overseas in the past three years, (4) have any relationships with any directors, senior management, substantial shareholders or controlling shareholders of the Company (as respectively defined in the Listing Rules), and (5) have any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other matter relating to the re-designation of Mr. Chearavanont, the appointments of Ms. Srichai and Mr. Na Muangtoun that need to be brought to the attention of the shareholders of the Company, and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express its gratitude to Mr. Seriburi for his valuable contributions to the Company during his tenure of office on the Board and as the Chief Executive Officer (Industrial Division) of the Company and Mr. Phityaisarakul for his valuable contributions to the Company during his tenure of office as the Chief Executive Officer (Biochemical Division) of the Company. At the same time, the Board wishes to congratulate Mr. Chearavanont and Mr. Na Muangtoun on his respective new roles with the Company and welcome Ms. Srichai in joining the Board.

## **CHANGE OF COMPOSITION OF BOARD COMMITTEE**

Following the above changes, the Remuneration Committee comprises Mr. Cheng Yuk Wo (Chairman), Ms. Cheung Marn Kay and Mr. Chawalit Na Muangtoun.

By Order of the Board  
**Thirayut Phityaisarakul**  
*Director*

Hong Kong, 24 February 2026

*As at the date of this announcement, the Board comprises Mr. Soopakij Chearavanont (Chairman and Executive Director), Mr. Thirayut Phityaisarakul, Mr. Nopadol Chiaravanont, Mr. Chawalit Na Muangtoun (each an Executive Director), Ms. Kobboon Srichai, Mr. Yoichi Ikezoe (each a Non-executive Director), Mr. Surasak Rounroengrom, Mr. Cheng Yuk Wo, Mr. Edward Ko Ming Tung and Ms. Cheung Marn Kay (each an Independent Non-executive Director).*